Group 1 - The National Health Commission of China announced the recognition of outstanding regions, collectives, and individuals in the construction of safe hospitals for the 2022-2023 period, with 61 regions, 545 collectives, and 572 individuals being honored [1] Group 2 - Tencent's cognitive training software "Tencent Brain Exercise" has received approval from the Guangdong Provincial Drug Administration for clinical application, aimed at improving cognitive abilities in patients with mild cognitive impairment, which affects nearly 40 million people in China [3] Group 3 - Yifan Pharmaceutical announced that its subsidiary Yifan Shanghai received the clinical trial approval notice for a growth hormone injection, which is a biosimilar to Novo Nordisk's product, intended for treating growth hormone deficiency in children and adults [4] Group 4 - Guobang Pharmaceutical's subsidiary Zhejiang Guobang received GMP certification for its Tylosin raw material, which will facilitate the company's expansion into overseas markets [5] Group 5 - Yimai Sunshine announced plans to acquire 70% of Gaomai Health for a total consideration of 54 million yuan, which will integrate Gaomai's financial performance into Yimai Sunshine's financial statements [7] Group 6 - Baize Medical listed on the Hong Kong Stock Exchange with an issue price of 4.22 HKD per share, raising a net amount of 468 million HKD, and operates eight hospitals across various regions in China [8] Group 7 - Yaojie Ankang listed on the Hong Kong Stock Exchange at a final offer price of 13.15 HKD per share, raising a net amount of 161.34 million HKD, focusing on developing innovative therapies for tumors and other diseases [10] Group 8 - Baiyoutai signed a licensing and commercialization agreement with SteinCares for BAT2406 in Brazil and Latin America, with a potential total transaction value of up to 10 million USD [12] Group 9 - Heptagon Pharmaceuticals entered a global strategic collaboration with Otsuka Pharmaceutical for the development of a BCMA/CD3 bispecific T cell engager, with potential payments totaling up to 623 million USD [13] Group 10 - Illumina announced an agreement to acquire SomaLogic for 350 million USD in cash, plus performance milestone payments, to integrate protein detection technology into its NGS platform [14] Group 11 - Jingtai Technology signed a pipeline licensing intention with DoveTree, with initial payments of 51 million and 49 million USD, and potential payments reaching several billion USD based on product sales [15]